OnKure Therapeutics (NASDAQ:OKUR) Earns “Buy” Rating from HC Wainwright

OnKure Therapeutics (NASDAQ:OKUR)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $40.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 127.53% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. Lifesci Capital raised shares of OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, October 10th. Oppenheimer started coverage on shares of OnKure Therapeutics in a research report on Thursday, October 10th. They set an “outperform” rating and a $35.00 price target on the stock.

OnKure Therapeutics Stock Up 2.3 %

NASDAQ:OKUR opened at $17.58 on Friday. OnKure Therapeutics has a one year low of $9.80 and a one year high of $77.60. The company has a market capitalization of $58.72 million, a P/E ratio of -1.05 and a beta of 0.21.

OnKure Therapeutics (NASDAQ:OKUR) last issued its earnings results on Thursday, November 7th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.13). As a group, equities research analysts anticipate that OnKure Therapeutics will post -3.87 earnings per share for the current year.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.